Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Meningitis

Generalities
Agent There are several agents causing meningitis.
1) Main Bacteria:
- Neisseria meningitidis (meningococcus): Gram negative diplococci. Main invasive serotypes are A, B, C, W135, X, and Y.
- Haemophilus influenza: Gram negative cocco-bacilli. There are 6 serotypes from (a) to (f). The serotype (b) is responsible of invasive infection.
- Streptococcus pneumonia (pneumococcus): Gram positive diplococci. There are more than 90 serotypes.
- Leptospira: spirochetes, Leptospira interrogans (26 serogroups)
- Listeria monocytogenes: Gram positive, rod-shapped
- Other bacterial agents: Staphylococcus, enteric bacteria, group B streptococci, Mycobacterium tuberculosis…
2) Virus:
- Mumps
- Measles
- West Nile virus: a Flavivirus
- Enterovirus: including Coxsackieviruses A (2-4, 7, 9-10), Coxsackieviruses B (1-6), Echoviruses (2, 5-7, 9-11, 14, 18, 30), Enterovirus 71, Poliovirus (1-3)
- Herpes Simplex virus (types 1 and 2): family Herpesviridae
- Varicella-Zoster virus: Human (alpha) Herpesvirus 3 (varicella-zoster) from the group Herpesvirus
- Adenovirus: Adenovirus, several types (1, 2, 3, 4, 5 and 7), genus Mastadenovirus, family Adenoviridae, - Lymphocytic choriomeningitis virus: an Arenavirus
- Sandfly fever viruses: genus Phlebovirus, family Bunyaviridae. They include more than 60 antigenically distinct virus serotypes. Two main groups are identified: a) Sandfly fever group including the Naples serocomplex (Karimabad virus, Arabia virus, Massilia virus, Punique virus, Tehran virus, Toscana virus …) and Sicilian serocomplex; and b) Uukuniemi group
-Other virus: arboviruses…
3) Parasites: - Candida albicans, cryptococcus…
Incubation period varies with the agent
Period of transmissibility varies with the agent
Reservoir varies with the agent
Modes of transmission varies with the agent
Clinical presentation varies with the agent
Resources
Case definition MOPH circular no. 52 (2007): Meningitis
MOPH circular no. 63 (2007): Neisseria meningitidis
MOPH circular no. 54 (2007): Haemophilus influenzae b
MOPH circular no. 36 (2012): West Nile Virus
Forms - Meningitis reporting form
- Meningitis investigation form
Data - Weekly report
    ...
    118
    ...
ATC Name B/G Ingredients Dosage Form Price
L01FE02 VECTIBIX BioTech Panitumumab - 400mg/20ml 400mg/20ml Injectable concentrated solution 147,763,999 L.L
L01FE02 VECTIBIX BioTech Panitumumab - 100mg/5ml 100mg/5ml Injectable concentrated solution 40,364,800 L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution L.L
L01FF01 OPDIVO BioTech Nivolumab - 100mg/10ml 100mg/10ml Injectable solution 117,224,380 L.L
L01FF01 OPDIVO BioTech Nivolumab - 40mg/4ml 40mg/4ml Injectable solution 51,234,726 L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01FF02 KEYTRUDA BioTech Pembrolizumab - 100mg/4ml 100mg/4ml Injectable solution 241,744,802 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution 227,939,689 L.L
L01FF03 IMFINZI BioTech Durvalumab - 500mg/10ml 500mg/10ml Injectable solution 227,939,689 L.L
L01FF03 IMFINZI BioTech Durvalumab - 120mg/2.4ml 120mg/2.4ml Injectable solution 59,776,110 L.L
L01FF03 IMFINZI BioTech Durvalumab - 120mg/2.4ml 120mg/2.4ml Injectable solution 59,776,110 L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution L.L
L01FF04 BAVENCIO BioTech Avelumab - 200mg/10ml 200mg/10ml Injectable concentrate for solution 100,111,133 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1200mg 1200mg Injectable concentrate for solution 375,054,619 L.L
L01FF05 TECENTRIQ BioTech Atezolizumab - 1875mg/15ml 1875mg/15ml Injectable solution 375,054,619 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 100mg/4ml 100mg/4ml Injectable solution L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrated solution 75,875,312 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 400mg 400mg Injectable concentrated solution 75,875,312 L.L
L01FG01 BEVACIREL BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution 49,744,595 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 92,353,609 L.L
L01FG01 BIVASTINA 400 BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 53,111,763 L.L
L01FG01 MVASI BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 58,035,926 L.L
L01FG01 STIVANT BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable concentrate for solution 27,359,527 L.L
L01FG01 ZIRABEV BioTech Bevacizumab - 400mg/16ml 400mg/16ml Injectable solution 49,965,229 L.L
    ...
    118
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025